RecruitingNCT06660147

Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

PAOLA-1 Ancillary Study: Retrospective Validation of KELIM as a Predictive and Prognostic Factor for Maintenance Treatment With PARP Inhibitor After Platinum-Based Chemotherapy in First-Line Ovarian Cancer

Sponsor

ARCAGY/ GINECO GROUP

Enrollment

327 participants

Start Date

Dec 11, 2023

Study Type

OBSERVATIONAL

Conditions

Ovarian Cancer

Summary

This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit from this treatment

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study re-analyses data from a large ovarian cancer trial (PAOLA-1) to validate a blood test measure called KELIM — which tracks how quickly a tumor marker (CA-125) drops during chemotherapy — as a way to predict who will benefit most from PARP inhibitor maintenance therapy after first-line treatment. **You may be eligible if...** - You were previously enrolled in the PAOLA-1 clinical trial for ovarian cancer - You consent to your data being used for research purposes **You may NOT be eligible if...** - You object to the use of your data for research purposes Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(24)

ICO Paul Papin

Angers, France

Sainte-Catherine Institut du Cancer Avignon-Provence

Avignon, France

CHRU Besançon - Hôpital Jean Minjoz

Besançon, France

Polyclinique Bordeaux Nord

Bordeaux, France

Centre François Baclesse

Caen, France

Centre Jean Perrin

Clermont-Ferrand, France

CHU Grenoble-Alpes - Site Nord (La Tronche)

Grenoble, France

Centre Hospitalier Départemental de Vendée

La Roche-sur-Yon, France

Centre Azuréen de Cancérologie

Mougins, France

Hôpital Privé du Confluent

Nantes, France

Groupe Hospitalier Diaconesses - Croix Saint-Simon

Paris, France

Hôpital Cochin

Paris, France

Hôpital Européen Georges Pompidou

Paris, France

Institut Curie

Paris, France

Clinique Francheville

Périgueux, France

HCL - Centre Hospitalier Lyon Sud

Pierre-Bénite, France

CHU de Poitiers - Hôpital de la Milétrie

Poitiers, France

Centre Eugène Marquis

Rennes, France

ICO - Centre René Gauducheau

Saint-Herblain, France

Oncopole Claudius Regaud - IUCT Oncopole

Toulouse, France

Clinique Pasteur

Toulouse, France

ICL - Centre Alexis Vautrin

Vandœuvre-lès-Nancy, France

Gustave Roussy

Villejuif, France

Centre Hospitalier Princesse Grace

Monaco, Monaco

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06660147

Related Trials

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT069150257 locations

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT057399814 locations

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

DESTINY-PANTUMOUR04

NCT0712400017 locations

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779157 locations